Molecular therapy of breast cancer: progress and future directions.
about
Genetics and Breast Cancer - Oncologists PerspectivesEstrogen receptor alpha interacts with mitochondrial protein HADHB and affects beta-oxidation activityClinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradiol-estrone ratio in estrogen-sensitive breast cancer cells"Iron-saturated" bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice.Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cellsLentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.Skp2 is a promising therapeutic target in breast cancer.CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signallingIdentification of miR-200a as a novel suppressor of connexin 43 in breast cancer cellsSynergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapyMechanism of Regulatory Effect of MicroRNA-206 on Connexin 43 in Distant Metastasis of Breast CancerRegulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progressionDNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice.The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cellsRANKL inhibition: a promising novel strategy for breast cancer treatment.Current role and safety profile of aromatase inhibitors in early breast cancer.Sulfatase inhibitors: a patent review.Drug treatment of cancer cell lines: a way to select for cancer stem cells?Inhibition of Macrophage CD36 Expression and Cellular Oxidized Low Density Lipoprotein (oxLDL) Accumulation by Tamoxifen: A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)γ-DEPENDENT MECHANISM.Bioactive cardinane sesquiterpenes from the stems of Alangium salviifolium.SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.Tamoxifen inhibits macrophage FABP4 expression through the combined effects of the GR and PPARγ pathways.Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.Profiling metabolic changes in breast cancer with targeted proteomics
P2860
Q28072876-98D1813E-9854-4DDA-8EDB-44BC49D950CCQ28260956-992B4C8F-3C59-47A9-9497-68F245584C7CQ33750749-A789D0E6-36D4-453F-A36C-8262090F211FQ34130698-296E15A9-7AED-4011-AD91-C17954CB217BQ34508653-87E1F89D-5096-4430-8E23-2DEFC01CDA49Q35551964-F2FFEC03-EF7A-4048-AFCC-7F3C6B06395BQ35600324-7E56A94E-6B3C-4AF5-A90D-AA0FE761F526Q35687208-5B94FC68-0580-46E9-9594-3162DFE8F1B5Q36075168-79031B2B-E376-4F03-A7DB-75F7B000C9C7Q36185088-43CB68B7-D1B8-41C2-8E29-32DDD2832A88Q36331426-193F6AD3-D18D-4256-B496-969BDDE4953FQ36703116-5145EAA4-8029-4470-A9EF-E7F3CF93ED4DQ36709368-C6DE76F9-1344-4C5D-9D2B-7FD33EE4DF1BQ37065354-BC773B02-A1F5-44FC-A71D-7389D9867B95Q37181439-B2EC4861-0FD1-4D21-838C-37DB748B7ABFQ37417960-DF13AF3A-1C0E-46D4-A6D5-7B6FE1ACB747Q37511632-00931A44-C0BC-4A6E-A5FD-01F96D49C1A4Q37865171-C64269C0-46C6-477E-9289-D23770EFCEC3Q37931895-DCAA7509-0A08-4E18-9C47-B51E04A67D5FQ38058531-2E73D089-3AA6-4266-AECB-F656F534C5EDQ38161343-41C3AA1C-AF35-49C4-A47F-C2E7ABFAF58BQ38760751-8319E8C8-EA02-43CC-9C72-C3ABF91A7335Q38913688-C64FE4CF-07C1-47E6-A822-D33920D099E4Q39032869-1C26F94B-5E10-493A-BB13-8F66C2211D6DQ45254004-592DEF19-40AF-425A-AF78-67949F6DE181Q49461096-FA012866-872E-4CEA-8B1C-8562491E7B90Q50874092-D077C0DB-52BE-4646-825E-EDCBC6721231Q52097904-FDCE7EA4-5964-4DED-BD6D-8140FCDC84C8Q57326021-88D29D6C-8272-48E8-8265-D1F9240DA6DE
P2860
Molecular therapy of breast cancer: progress and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular therapy of breast cancer: progress and future directions.
@en
Molecular therapy of breast cancer: progress and future directions.
@nl
type
label
Molecular therapy of breast cancer: progress and future directions.
@en
Molecular therapy of breast cancer: progress and future directions.
@nl
prefLabel
Molecular therapy of breast cancer: progress and future directions.
@en
Molecular therapy of breast cancer: progress and future directions.
@nl
P2093
P2860
P356
P1476
Molecular therapy of breast cancer: progress and future directions.
@en
P2093
Arezki Azzi
Cheng Wang
Donald Poirier
Jiong Chen
Mausumi Mazumdar
P2860
P2888
P304
P356
10.1038/NRENDO.2010.92
P577
2010-07-20T00:00:00Z